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Abstract
Setting: National Institute of Tuberculosis and Respiratory Diseases (erstwhile Lala Ram Sarup Institute) in Delhi, India.
Objectives: To evaluate before and after the introduction of the line Probe Assay (LPA) a) the overall time to MDR-TB
diagnosis and treatment initiation; b) the step-by-step time lapse at each stage of patient management; and c) the lost to
follow-up rates.
Methods: A retrospective cohort analysis was done using data on MDR-TB patients diagnosed during 2009–2012 under
Revised National Tuberculosis Control Programme at the institute.
Results: Following the introduction of the LPA in 2011, the overall median time from identification of patients suspected for
MDR-TB to the initiation of treatment was reduced from 157 days (IQR 127–200) to 38 days (IQR 30–79). This reduction was
attributed mainly to a lower diagnosis time at the laboratory. Lost to follow-up rates were also significantly reduced after
introduction of the LPA (12% versus 39% pre-PLA).
Conclusion: Introduction of the LPA was associated with a major reduction in the delay between identification of patients
suspected for MDR-TB and initiation of treatment, attributed mainly to a reduction in diagnostic time in the laboratory.
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Introduction
Among patients with multidrug resistant- tuberculosis (MDR-
TB), delays in diagnosis and treatment initiation are frequently
observed, resulting in an increased risk of disease complications
and high mortality and pre-treatment lost to follow-up rates. In
addition, such delays lead to an extended period of TB infectivity
within the community, resulting in higher transmission rates,
higher mortality and morbidity [1].
As in-vitro confirmation of resistance to Isoniazid and
Rifampicin (the two most important first line anti-TB drugs) is
essential for the diagnosis of MDR-TB, a major reason for the
delay in starting MDR-TB treatment is the prolonged time taken
by the laboratory to make the diagnosis of drug resistance [2–4].
Most national tuberculosis programme laboratories in high TB
burden countries use either solid or liquid culture media for drug
sensitivity testing (DST) which respectively take on an average 84
and 42 days to make a diagnosis [5,6].
India is one of the highest TB burden countries in the world
with about 64,000 estimated cases of MDR-TB annually [7]. India
began implementation of programmatic management of drug
resistant tuberculosis in 2007 and has gradually expanded the
services nationwide. However progress was slow due to limited
laboratory capacity and long turn-around times using established
diagnostic methods described earlier [7–9]. In 2011, the Line
Probe Assay (LPA) was introduced as a new diagnostic technique
in the Indian National TB Programme. It is a method based on
nucleic acid amplification, permitting rapid detection of mutations
in genes coding for resistance to Rifampicin and Isoniazid (Hain
test). The LPA test only requires an average time of two days to
diagnose MDR-TB, which is vastly shorter than the previous
diagnostic methods [9–12]. Currently there are 41 laboratories
nationwide implementing the LPA tests and the country plans to
establish more laboratories with LPA testing facilities. Shortening
the time to diagnosis of MDR-TB has the potential to improve
access to appropriate treatment and reduce losses to follow-up. To
date however, there is no published literature documenting the
associated programmatic impact of introducing LPA for MDR-TB
diagnosis in India.
In Delhi, India, we therefore compared the following param-
eters before and after the introduction of the LPA: a) the overall
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time interval between suspicion of patients for MDR-TB and their
treatment initiation and b) the time intervals for four different steps
of patient management between suspicion of patients for MDR-
TB and treatment initiation. Additionally, we compared pre-
treatment losses to follow-up rates before and after introduction of
the LPA test.
Methods
Design
This was a retrospective cohort study using routinely collected
programme data.
Setting
At the time of the study, Delhi state, with a population of 16.8
million and an estimated TB burden of 55,000 patients had two
certified laboratories for the diagnosis of MDR-TB, both of which
introduced the LPA in October 2011. Before this date, the
laboratories were using solid culture and DST for the patients
under the National programme. There are four Drug Resistant
TB Centres (DR-TB centres) for initiating MDR-TB treatment
and managing diagnosed MDR-TB patients. One of these
diagnostic laboratories and the associated DR-TB centre is located
at the National Institute of TB & Respiratory Diseases (NITRD,
erstwhile Lala Ram Sarup Institute). The laboratory of the
institute is also one of the National Reference Laboratory for the
National TB Programme in India.
Diagnosis and treatment of MDR-TB
From 2009 till September 2011, the criteria for suspecting
MDR-TB under the national programme were: treatment failures
among new TB cases, smear positive cases that remained smear
positive after the fourth month of treatment with Retreatment
regimen, and pulmonary TB cases who were contacts of known
MDR-TB cases (Criteria A-Pre LPA cohort). During this period,
solid culture (LJ Media) and drug sensitivity testing (1% proportion
method) was done [13]. From October’11, with introduction of
rapid diagnostic method (LPA) the criteria for presuming MDR-
TB were expanded to also include all smear positive and negative
previously treated pulmonary TB cases at diagnosis, any smear
positive follow-up results in new or previously treated cases, and all
HIV/TB co-infected cases at diagnosis (Criteria B & C-Post LPA
cohort). During this period, the LPA (Hain test) was done; a
molecular test which identifies mutations conferring resistance to
Rifampicin and Isoniazid. This test was done only on smear
positive samples [14]. All sputum negative samples were put on
liquid culture (MGIT) and LPA was done from these cultures.
TB patients who fulfilled the criteria for suspecting MDR-TB
were identified in the peripheral DOT centres by medical officers
and lab technicians, and referred to the lab of the National
Institute of TB and Respiratory Diseases for diagnosis and further
management. All patients diagnosed as resistant to Rifampicin and
Isoniazid (MDR-TB) or resistant to Rifampicin and sensitive to
Isoniazid were referred to a Drug Resistant TB Centre for
initiation of MDR-TB treatment. At this Drug Resistant TB
centre, patients were hospitalised and a pre-treatment evaluation
was performed: treatment was initiated after approval by the Drug
Resistant TB Centre committee. Treatment of MDR-TB under
the National TB programme is the standard drug regimen
comprising of Intensive phase of 6 to 9 months of Kanamycin,
Livofloxacin, Ethionamide, Cycloserine, Pyrazinamide, and Eth-
ambutol followed by continuation phase of 18 months of
Livofloxacin, Ehionamide, Cycloserin, and Ethambutol. PAS is
used as a substitute drug.
Inclusion criteria and study population
The study inluded all patients enrolled between January 2009
and December 2012 at the NITRD laboratory who met the
following criteria: a) diagnosed as MDR-TB either by solid/liquid
culture & DST or LPA at the Institute’s laboratory, b) were either
pretreatment smear positive retreatment patients or had positive
follow-up sputum smears while on new or retreatment regimens, c)
started treatment from the NITRD DR-TB centre, and d) had a
complete record of dates at the time of data collection. Patients
enrolled between January 2009 and September 2011 comprised
the pre-LPA group. The post-LPA phase was from October 2011
and December 2012. For the post-LPA period, to assess various
time periods between suspecting MDR-TB to treatment initiation,
we collected data for 2 consecutive quarters from October 2011 to
March, 2012 with cut-off date of 30th March 2012. During the
pre-LPA phase, a total of 121 patients were initiated on treatment,
and of these 51 were included in the study based on the inclusion
criteria. Patients enrolled between October 2011 and December
2012 comprised the post-LPA group. During this phase, 433
patients were enrolled on MDR-TB treatment, and of these 83
were included in the study based on inclusion criteria and cut-off
date. The time taken from suspecting MDR-TB in patients to
initiation of MDR-TB treatment at the Drug Resistant TB centre
was evaluated in each group.
To compare the pre-treatment lost to follow-up rates between
the pre- and post-LPA phase, data on all patients suspected of
MDR-TB identified between January 2009 and December 2012
were collected.
Data sources, variables and definitions
Data on the socio-demographic characteristics of the study
population were sourced from the referral for culture DST
Register, laboratory register and TB register for MDR-TB
patients. The data included the following data variables: age,
sex, type of TB, and dates pertaining to diagnosis and treatment
initiation.
Data to examine the time intervals between MDR-TB suspicion
and treatment were sourced from the Revised National Tubercu-
losis Control Programme records (TB treatment cards, Referral for
Culture & DST forms and Drug Resistant TB register). The main
study variables included the dates of suspecting MDR-TB in the
patient, laboratory referral, diagnosis, and treatment initiation;
The total time from date of suspecting MDR-TB to initiation of
treatment was sub-divided as: a) time from suspecting MDR-TB to
laboratory referral; b) time from the specimens reaching the
laboratory to MDR-TB confirmation; c) time from MDR-TB
confirmation to presentation at the DR-TB centre; and d) time
from presentation at the DR-TB centre to MDR-TB treatment
initiation.
Data to assess lost to follow-up were sourced from Referral for
culture and DST register, Laboratory reports and Drug resistant
TB (DR-TB)registers; Patients diagnosed as MDR-TB but not
enrolled for treatment in DR-TB register were considered lost to
follow-up. All data were collected retrospectively.
Data validation, entry and analysis
Data validation was done by comparing the data from MDR-
TB register, individual treatment cards and treatment files, and
cross-checking all the records. Data were double-entered intoE-
piData v.3.1 (EpiData Association, Odense, Denmark), and cross-
verified for consistency.
Data were analysed using EpiData Analysis software v.2.2.1.171
(EpiData Association Odense, Denmark): simple summary statis-
tics were calculated, and differences between groups were
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compared using Chi-square test and Kruskal Wallis test as
appropriate. A p-value ,0.05 was taken as statistically significant.
Data concerning the pre-treatment lost to follow-up rates were
extracted from the quarterly programme reports of Drug Resistant
TB Centre of NITRD.
Ethics
This study was reviewed and approved by the Institutional
Ethics Committee of the National Institute of TB and Respiratory
Diseases, New Delhi, India. In addition, this study met the
Me´decins Sans Frontie`res’ Ethics Review Board (Geneva,
Switzerland)-approved criteria for analysis of routinely-collected
programme data and was also approved by the Ethics Advisory
Group of the International Union against Tuberculosis and Lung
Disease, Paris, France. As this study involved review of routinely
collected patient data from hospital records under confidentiality,
the ethics committees waived us from obtaining written consent
from patients.
Results
A total of 51 and 83 patients fulfilled the inclusion criteria for
assessment of the time taken from suspecting MDR-TB to
initiation of MDR-TB treatment for the pre- and post-LPA study
periods respectively. There were no differences in the demo-
graphic characteristics of these two groups (Table 1).
The overall median time from suspecting MDR-TB to the
initiation of treatment was reduced from 157 (IQR 127–200) days
to 38 days (IQR 30–79), shown in Table 2. The major reason for
this reduction was the time taken by the laboratory to diagnose
MDR-TB and provide the results, which decreased from 107 days
(IQR 79–131) to 5days (IQR 3–6) (Step 2). The intervals between
identification of presumed MDR-TB cases and referral to the
laboratory for specimens decreased from 12 days (IQR 7–29) to 9
days (IQR 4–31) (Step 1) and between laboratory notification and
patients reporting to the Drug Resistant TB Centre from 12 days
(IQR 4–26) to 7 days (IQR 5–13) (step 3), but the delays were not
significantly different pre-and post-LPA. The time taken by the
Drug Resistant TB centre to initiate treatment increased from 8
days (IQR 7–13) to 12days (IQR 9–17) (step 4).
The cohort used for pre-treatment lost to follow-up analysis
included a total of 736 and 3078 patients suspected for MDR-TB
during the pre-LPA and post-LPA periods respectively (Figure 1).
Post-LPA, the losses were significantly reduced between identifi-
cation of patient suspected for MDR-TB and specimens reaching
the laboratory, and between diagnosis and treatment initiation.
Finally, the overall pre-treatment lost to follow-up from
suspicion of patients for MDR-TB to start of treatment was
significantly lower during the post-LPA period compared to the
pre-LPA period.
Discussion
We believe that this is first study from India to assess the impact
of introduction of LPA on the length of time between identification
of presumed MDR-TB, diagnosis of MDR-TB and initiation of
treatment under routine programmatic conditions. The introduc-
tion of LPA significantly reduced the time taken by the laboratory
to diagnose MDR-TB. As a result, the total time taken to diagnose
and initiate MDR-TB patients on treatment was reduced to an
average of one and a half months from an average of five months
previously.
The study has several strengths. First, it was carried out in a
tertiary referral institute which is a National Reference laboratory
and it had all the standard quality control measures in place. Thus,
the reported results of the sputum culture and DST were highly
reliable. Second, the study was conducted in a routine programme
setting and therefore is likely to reflect the reality on the ground.
Finally, data pertaining to the study were validated by us by cross
checking multiple registers and we therefore believe that they are
robust.
The results of this study are comparable to those reported from
South Africa [3] in which 75% of patients with MDR-TB had a
delay in diagnosis and treatment of up to 22 weeks leading to
prolonged infectivity and morbidity. From a public health
perspective, reducing the period between diagnosis and treatment
initiation by the introduction of the LPA has direct benefits for
both the patient and the community. Patients benefit from early
diagnosis and earlier initiation of appropriate treatment which
should result in reduced morbidity and mortality. The community
Table 1. Demographic characteristics of MDR-TB patients according to the method of MDR-TB diagnosis used between 2009–
2012 - New Delhi, India.
Variable Pre-LPA
a Post-LPAb
n (%) n (%) P-value
Total 51 83
Sex
Male 29(57) 54(65) 0.34
Female 22(43) 29(35) -
Age (years)
,35 32(63) 59(71) 0.31
$35 19(37) 24(29) -
Median, years (IQR) 30(22–40) 27(21–37) 0.31
TB category
New case 10(20) 16(19) 0.96
Previously treated 41(80) 67(81) -
aSolid culture & Drug Sensitivity Testing (DST),
bLPA: Line Probe Assay, MDR-TB: Multidrug resistant Tuberculosis, IQR: Inter-quartile Range.
doi:10.1371/journal.pone.0102989.t001
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Table 2. Comparison of time from identification of patients suspected for MDR-TB to initiation of MDR-TB treatment between pre-
and post-LPA period - New Delhi, India.
Steps between identification of patients suspected for MDR-TB and treatment initiation Median time, days (IQR) P-value*
Pre-LPAa Post-LPAb
Step 1: Time from identification of patients suspected for MDR-TB to submission of samples
in the laboratory
12(7–29) 9(4–31) 0.07
Step 2: Time taken in the laboratory to test and provide the MDR-TB report 107(79–131) 5(3–6) ,0.0001
Step 3: Time taken from laboratory report to patient reporting to Drug Resistant TB centre 12(4–26) 7(5–13) 0.3
Step 4: Time taken by Drug Resistant TB centre to initiate treatment 8(7–13) 12(9–17) 0.006
TOTAL (Step 1–Step 4) 157(127–200) 38(30–79) ,0.001
*P-value generated using the Wilcoxon rank sum test; IQR = Inter-quartile range; MDR-TB =Multidrug resistant Tuberculosis;
aSolid/liquid culture & Drug Sensitivity Testing (DST).
bLPA: Line Probe Assay.
doi:10.1371/journal.pone.0102989.t002
Figure 1. Pre-treatment loss to follow-up rate among MDR-TB suspects before and after diagnosis is in the pre-LPA and post-LPA
periods at New Delhi, India.
doi:10.1371/journal.pone.0102989.g001
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benefits from reduced transmission of MDR-TB as a result of
reduced duration of infectivity of index patients.
Although the overall delay between suspicion of MDR-TB and
initiation of treatment was reduced, the fact that it still takes on
average a month and a half for the diagnosis and initiation of
treatment for MDR-TB suggests that there is a need to further
review and improve the process. First, the identification of persons
with suspicion for MDR-TB needs to improve, by maintaining a
high level of vigilance and rapid appropriate investigation of
patients who are not responding to first line anti-TB treatment.
Second, time delays at the laboratory could be further reduced by
the introduction of an automated cartridge based nucleic acid
amplification test (CB-NAAT, such as Xpert MTB/RIF) that has
the potential to diagnose MDR-TB among high risk individuals in
a matter of two hours at the laboratory, thereby providing results
on the same day. CB-NAAT also requires less laboratory
sophistication and human resource expertise than LPA in
conducting tests for MDR-TB. Third, paradoxically the time to
initiate MDR-TB treatment by the DR-TB centre after diagnosis
was found to be longer with the LPA system compared with using
the established solid and liquid culture media. One of the possible
reasons for this could be that the capacity of the NITRD Drug
Resistant TB centre in terms of the number of patients that can be
handled remained the same during the entire period. This may
have resulted in delays in referring patients for treatment (due to
queuing up of patients for hospital admission). This issue needs to
be confirmed by a further in-depth study (which was beyond the
scope of the present study) and if found to be true, it must be
addressed by increasing the number of staff and the capacity of
centres to initiate more MDR-TB patients on treatment [15].
Several limitations of the study were also identified. First,
although LPA has clearly reduced the time to diagnosis, the
reduction in total time taken between diagnosis and treatment
could have been influenced by other factors, such as better
recording and reporting and the recent introduction of supervisors
for MDR-TB at the district level. Second, the data compiled for
the lost to follow-up rates are from the routine data produced by
the programme. During the LPA period, there may have been
patients who were diagnosed by other certified laboratories in
Delhi or by solid/liquid culture used elsewhere. However, we
think that the number of such cases is likely to be small and is
unlikely to impact on the current study results. Third, LPA as a
technology for the diagnosis of MDR-TB poses some major
operational challenges for its implementation and scale-up in
resource-limited settings. The assay can be done only on sputum
specimens that are smear positive, it is expensive, it requires
sophisticated laboratory equipment, quality control measures must
be in place, human resources must be trained and there must be a
backup of solid/liquid culture to manage sputum specimens that
are smear negative.
Conclusions and recommendations
The study shows that the introduction of LPA testing has a
major impact on the management of MDR-TB in Delhi, India. It
reduced the overall time from suspicion of patients for MDR-TB
to initiation of treatment by effectively reducing the laboratory
diagnostic time. At the same time the Drug Resistant TB Centres
may need to increase their capacity to deal with the increased load
of MDR-TB patients resulting from introduction of LPA. These
findings may help to improve the management and treatment of
MDR-TB in India.
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